{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:20:05Z","timestamp":1775305205727,"version":"3.50.1"},"reference-count":88,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/ppo.0b013e3181c51c8e","type":"journal-article","created":{"date-parts":[[2009,12,12]],"date-time":"2009-12-12T08:36:22Z","timestamp":1260606982000},"page":"511-518","source":"Crossref","is-referenced-by-count":11,"title":["Future Novel Single Agent and Combination Therapies"],"prefix":"10.1097","volume":"15","author":[{"given":"Diana","family":"Cirstea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Vallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210203","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008.","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"R2-10-20210203","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma.","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"R3-10-20210203","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"R4-10-20210203","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"R5-10-20210203","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"R6-10-20210203","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"R8-10-20210203","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"R9-10-20210203","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2141.2009.07728.x","article-title":"Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.","volume":"146","author":"Chen","year":"2009","journal-title":"Br J Haematol"},{"key":"R10-10-20210203","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"R11-10-20210203","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"suppl 18","key":"R12-10-20210203","first-page":"LBA8025","article-title":"Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol.","volume":"25","author":"Rajkumar","year":"2007","journal-title":"Annual Meeting Abstracts"},{"key":"R14-10-20210203","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V112.11.864.864","article-title":"Initial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM).","volume":"112","author":"Jagannath","year":"2008","journal-title":"Blood"},{"issue":"suppl 15","key":"R15-10-20210203","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/jco.2009.27.15_suppl.8504","article-title":"Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM).","volume":"27","author":"Jagannath","year":"2009","journal-title":"J Clin Oncol"},{"key":"R16-10-20210203","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.V112.11.865.865","article-title":"Initial results of PX-171-04, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM).","volume":"112","author":"Vij","year":"2008","journal-title":"Blood"},{"key":"R18-10-20210203","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib.","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"R19-10-20210203","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","article-title":"CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.","volume":"111","author":"Piva","year":"2008","journal-title":"Blood"},{"key":"R21-10-20210203","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2007-08-105601","article-title":"Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.","volume":"111","author":"Chauhan","year":"2008","journal-title":"Blood"},{"key":"R22-10-20210203","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma.","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"R23-10-20210203","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"R24-10-20210203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"R25-10-20210203","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4065\/79.7.875","article-title":"Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.","volume":"79","author":"Richardson","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"R26-10-20210203","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents.","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R27-10-20210203","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"R28-10-20210203","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","article-title":"Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.","volume":"15","author":"Gupta","year":"2001","journal-title":"Leukemia"},{"key":"R29-10-20210203","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood.V112.11.866.866","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone (pom\/dex) is highly effective therapy in relapsed multiple myeloma.","volume":"112","author":"Lacy","year":"2008","journal-title":"Blood"},{"key":"R30-10-20210203","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1073\/pnas.2536759100","article-title":"Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.","volume":"101","author":"Mitsiades","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"R31-10-20210203","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood-2003-01-0233","article-title":"NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.","volume":"102","author":"Catley","year":"2003","journal-title":"Blood"},{"key":"R32-10-20210203","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.","volume":"24","author":"O'Connor","year":"2006","journal-title":"J Clin Oncol"},{"key":"R33-10-20210203","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R34-10-20210203","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood.V112.11.2774.2774","article-title":"A phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma.","volume":"112","author":"Wolf","year":"2008","journal-title":"Blood"},{"key":"R35-10-20210203","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V112.11.958.958","article-title":"Phase IA\/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies.","volume":"112","author":"Ottmann","year":"2008","journal-title":"Blood"},{"key":"R36-10-20210203","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-08-4472","article-title":"Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.","volume":"69","author":"Deleu","year":"2009","journal-title":"Cancer Res"},{"key":"R37-10-20210203","doi-asserted-by":"crossref","first-page":"8548","DOI":"10.1200\/jco.2008.26.15_suppl.8548","article-title":"Phase I trial of vorinostat plus bortezomib (bort) in relapsed\/refractory multiple myeloma (mm) patients (pts).","volume":"26","author":"Badros","year":"2008","journal-title":"J Clin Oncol"},{"key":"R38-10-20210203","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V112.11.3698.3698","article-title":"High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I\/II clinical trial.","volume":"112","author":"Harrison","year":"2008","journal-title":"Blood"},{"key":"R39-10-20210203","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood.V112.11.3705.3705","article-title":"A phase I study of vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.","volume":"112","author":"Siegel","year":"2008","journal-title":"Blood"},{"key":"R40-10-20210203","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood.V110.11.1172.1172","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma.","volume":"110","author":"Weber","year":"2007","journal-title":"Blood"},{"key":"R43-10-20210203","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells.","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"R45-10-20210203","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2141.2007.06714.x","article-title":"Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.","volume":"138","author":"Hideshima","year":"2007","journal-title":"Br J Haematol"},{"key":"R46-10-20210203","first-page":"5850","article-title":"Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3\u2032-kinase\/AKT signaling.","volume":"63","author":"Tai","year":"2003","journal-title":"Cancer Res"},{"key":"R47-10-20210203","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1182\/blood.V98.9.2853","article-title":"The AKT kinase is activated in multiple myeloma tumor cells.","volume":"98","author":"Hsu","year":"2001","journal-title":"Blood"},{"key":"R48-10-20210203","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","article-title":"Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.","volume":"107","author":"Hideshima","year":"2006","journal-title":"Blood"},{"key":"R49-10-20210203","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2006-04-016824","article-title":"Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.","volume":"109","author":"Gajate","year":"2007","journal-title":"Blood"},{"key":"R50-10-20210203","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood.V112.11.870.870","article-title":"Phase I\/II results of a multicenter trial of perifosine (KRX-0401) bortezomib in patients with relapsed or relapsed\/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib.","volume":"112","author":"Richardson","year":"2008","journal-title":"Blood"},{"key":"R51-10-20210203","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V112.11.3691.3691","article-title":"Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).","volume":"112","author":"Jakubowiak","year":"2008","journal-title":"Blood"},{"key":"R52-10-20210203","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood-2006-08-042747","article-title":"Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).","volume":"109","author":"Podar","year":"2007","journal-title":"Blood"},{"key":"R53-10-20210203","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1200\/JCO.2005.05.024","article-title":"Identification and validation of novel therapeutic targets for multiple myeloma.","volume":"23","author":"Hideshima","year":"2005","journal-title":"J Clin Oncol"},{"key":"R56-10-20210203","doi-asserted-by":"crossref","first-page":"15712","DOI":"10.1074\/jbc.M200043200","article-title":"Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.","volume":"277","author":"Shi","year":"2002","journal-title":"J Biol Chem"},{"key":"R57-10-20210203","first-page":"5027","article-title":"Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.","volume":"62","author":"Shi","year":"2002","journal-title":"Cancer Res"},{"key":"R58-10-20210203","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2002-08-2640","article-title":"Downstream effectors of oncogenic ras in multiple myeloma cells.","volume":"101","author":"Hu","year":"2003","journal-title":"Blood"},{"key":"R59-10-20210203","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1182\/blood-2004-06-2281","article-title":"Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.","volume":"104","author":"Raje","year":"2004","journal-title":"Blood"},{"key":"R60-10-20210203","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2003-05-1543","article-title":"Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.","volume":"103","author":"Str\u00f6mberg","year":"2004","journal-title":"Blood"},{"key":"R61-10-20210203","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-05-2447","article-title":"Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.","volume":"66","author":"Yan","year":"2006","journal-title":"Cancer Res"},{"key":"R62-10-20210203","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1182\/blood-2004-03-1153","article-title":"In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.","volume":"104","author":"Frost","year":"2004","journal-title":"Blood"},{"key":"R63-10-20210203","first-page":"1496","article-title":"The mTOR inhibitor RAD001 (everolimus) is active against multiple myeloma cells in vitro and in vivo.","volume":"104","author":"Mitsiades","year":"2004","journal-title":"ASH Annual Meeting Abstracts"},{"key":"R64-10-20210203","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","article-title":"mTOR and cancer therapy.","volume":"25","author":"Easton","year":"2006","journal-title":"Oncogene"},{"key":"R65-10-20210203","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents.","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R66-10-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer.","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"R67-10-20210203","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.leukres.2009.01.039","article-title":"Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.","volume":"33","author":"Farag","year":"2009","journal-title":"Leuk Res"},{"key":"R68-10-20210203","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"R69-10-20210203","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.","volume":"65","author":"Sun","year":"2005","journal-title":"Cancer Res"},{"key":"R70-10-20210203","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"R71-10-20210203","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1182\/blood.V112.11.3663.3663","article-title":"Combination of Nab-rapamycin and perifosine induces synergistic cytotoxicity and antitumor activity via autophagy and apoptosis in multiple myeloma (MM).","volume":"112","author":"Cirstea","year":"2008","journal-title":"Blood"},{"key":"R72-10-20210203","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1182\/blood.V112.11.3696.3696","article-title":"Phase I trial of CCI-779 (temsirolimus) and weekly bortezomib in relapsed and\/or refractory multiple myeloma.","volume":"112","author":"Ghobrial","year":"2008","journal-title":"Blood"},{"key":"R73-10-20210203","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma.","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J Clin Oncol"},{"key":"R74-10-20210203","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","article-title":"A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6.","volume":"66","author":"Baughn","year":"2006","journal-title":"Cancer Res"},{"key":"R75-10-20210203","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/blood-2005-01-0320","article-title":"Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.","volume":"106","author":"Raje","year":"2005","journal-title":"Blood"},{"key":"R76-10-20210203","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/leu.2008.378","article-title":"Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.","volume":"23","author":"Raje","year":"2009","journal-title":"Leukemia"},{"key":"R77-10-20210203","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1002\/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O","article-title":"IL-6 up-regulates mcl-1 in human myeloma cells through JAK\/STAT rather than ras\/MAP kinase pathway.","volume":"29","author":"Puthier","year":"1999","journal-title":"Eur J Immunol"},{"key":"R78-10-20210203","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1365-2141.1999.01705.x","article-title":"Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.","volume":"107","author":"Puthier","year":"1999","journal-title":"Br J Haematol"},{"key":"R79-10-20210203","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V112.11.2759.2759","article-title":"RGB 286638, a novel multi-targeted small molecule inhibitor, induces multiple myeloma (MM) cell death through abrogation of CDK-dependent and independent survival mechanisms.","volume":"112","author":"Cirstea","year":"2008","journal-title":"Blood"},{"key":"R80-10-20210203","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood.V112.11.251.251","article-title":"ASH 2008-AT7519, a novel small molecule multi-cyclin dependent kinase inhibitor, induces apoptosis in multiple myeloma VIA GSK3.","volume":"112","author":"Santo","year":"2008","journal-title":"Blood"},{"key":"R81-10-20210203","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.4049\/jimmunol.144.11.4226","article-title":"IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release.","volume":"144","author":"Kurihara","year":"1990","journal-title":"J Immunol"},{"key":"R82-10-20210203","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1158\/1078-0432.CCR-07-1293","article-title":"Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.","volume":"13","author":"Voorhees","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R83-10-20210203","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"R84-10-20210203","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","article-title":"Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.","volume":"13","author":"Neri","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R85-10-20210203","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res"},{"key":"R86-10-20210203","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/leu.2008.81","article-title":"Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.","volume":"22","author":"Shammas","year":"2008","journal-title":"Leukemia"},{"key":"R87-10-20210203","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood.V112.11.3701.3701","article-title":"Results of a phase I study of GRN163L, a direct inhibitor of telomerase, in patients with relapsed and refractory multiple myeloma (MM).","volume":"112","author":"Chanan-Khan","year":"2008","journal-title":"Blood"},{"key":"R88-10-20210203","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/humu.1177","article-title":"High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.","volume":"18","author":"Bezieau","year":"2001","journal-title":"Hum Mutat"},{"key":"R89-10-20210203","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2003-08-2764","article-title":"Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic\/tumor survival pathways in patients with advanced multiple myeloma.","volume":"103","author":"Alsina","year":"2004","journal-title":"Blood"},{"key":"R90-10-20210203","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1078-0432.CCR-05-1792","article-title":"Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.","volume":"12","author":"Yanamandra","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R91-10-20210203","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1182\/blood.V112.11.3706.3706","article-title":"A phase i mmrc clinical trial testing the combination of bortezomib and tipifarnib in relapsed\/refractory multiple myeloma.","volume":"112","author":"Lonial","year":"2008","journal-title":"Blood"},{"issue":"suppl","key":"R92-10-20210203","first-page":"Abstract","article-title":"A phase II trial of sorafenib in patients with relapsing and resistant multiple myeloma (MM) previously treated with bortezomib (S0434).","volume":"27","author":"Srkalovic","year":"2009","journal-title":"J Clin Oncol"},{"key":"R93-10-20210203","first-page":"409","article-title":"Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: phase 1 results.","volume":"110","author":"Orlowski","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R94-10-20210203","first-page":"411","article-title":"Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies.","volume":"110","author":"Alsina","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R95-10-20210203","first-page":"406","article-title":"A multicenter phase 1 clinical trial of tanespimycin (KOS-953) bortezomib (BZ): encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM).","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R96-10-20210203","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.V112.11.871.871","article-title":"Vorinostat plus bortezomib for the treatment of relapsed\/refractory multiple myeloma: early clinical experience.","volume":"112","author":"Weber","year":"2008","journal-title":"Blood"},{"key":"R97-10-20210203","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood.V112.11.2781.2781","article-title":"A phase IB, multicenter, open-label, dose-escalation study of oral panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma.","volume":"112","author":"Siegel","year":"2008","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0b013e3181c51c8e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T21:39:05Z","timestamp":1685223545000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-200911000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e3181c51c8e","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}